Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala @PennMedicine #radonc

Led by fellow Dr. John Matthew & supervised by Dr. Phil Wong, our group examined risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study. @LancetRH_Americ https://t.co/OweLZMvQXP

Here's a patient recently randomized on our ARREST2 phase 2/3 RCT. Sixteen pulmonary mets, 35 Gy in 5 fractions. Constraints: V13.5 Gy <37%, 1500 cc of lung <12.5 Gy

https://t.co/fD8wo72eJW

Academic medicine is 51 pages of "we regret to inform you" emails

🚀 Why Radiation Oncology Needs to Stop Playing Defense and Start Playing Offense I recently wrote a post on entrepreneurship across medical specialties, and the findings were eye-opening. While dermatology, radiology, and cardiology have robust entrepreneurial ecosystems

When distributing an abstract or manuscript for review by your colleagues, always put like v_14 at the end of the attached file name to make it seem like you’ve been absolutely grinding on previous drafts before you shared it. #ASH25 #lifehack

🚨🚨🚨 We are activating this single-arm phase 2 trial of hypofractionated RT to oligoprogressive metastatic #melanoma, up to 10 lesions + extensive specimen collection for correlatives. There's an unmet need in this area - hope results of the trial will benefit more patients.

Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol @Silke_Gillessen, @Prof_Nick_James, @AshwinUrol, and colleagues https://t.co/esZJWCiFaj

Some ask if patients with limited metastatic disease can be cured. The answer is clearly yes. We’ve known that since the 1930’s, and it was very clearly articulated in this book from the 1960s. In 2026 we’ll report the final outcomes from SABR-COMET, 10 years after closure.

In patients with oral cavity squamous cell carcinoma, adjuvant chemotherapy is beneficial in patients with major extranodal extension (ENE), but may not be beneficial in patients with minor ENE. https://t.co/Jq9VWBGoV0

Eliminating the PTV as a concept is a provocative idea. This editorial is worth a read... https://t.co/c9Q0BEPq0C

💡Seminal international 🇺🇸🇨🇦 efforts evaluating proactive vs reactive swallowing therapy during HNRT. - No meaningful difference b/w 3 arms ➡️ allows choice based on patient/clinic factors. Congrats @kahutcheson @MartinoUofT @NeilWoodyMD @pmcancercentre

🚨 PERSEPCTIVE 🚨 TGFβ has a well-established role in cancer, yet its blockade has 🔁ly failed in trials. Barcellos-Hoff & Yom use HPV-driven cancers as a model to explain this & emphasize the need for new strategies to enhance therapeutic efficacy. https://t.co/9Wf1cVvq8x

Our manuscript “Accuracy and Prognosis of ENE on Radiologic Imaging in HPV+OPC: an HNCIG real-world study” is now published in @IJROBP . Read below! https://t.co/Hr0ZekuqIx

🔥 Hot off the press: Ralph Weichselbaum, MD, and his team published a new study in @Nature demonstrating that high-dose radiation to primary tumors can unexpectedly promote tumor growth at metastatic sites. @rweichselbaum @AndrasPiffko @UChicagoRadonc https://t.co/yQLKw3gTor

Reclassifying each N category 1 stratum higher for imaging-detected extranodal extension-positive disease resulted in better disease-free and overall survival in patients human papillomavirus–positive oropharyngeal carcinoma. https://t.co/UVitMyooHX @DrMLChua

Excellent trial. Would be interested to see results stratifying on whether primary is controlled. And of course the use of modern day IO after. @naummalik

In this paper, we analyzed the @UTSW_RadOnc experience with adapt-on-demand for H&N squamous cell carcinoma using the Varian Ethos system. TL/DR: Significant (and I think meaningful) improvement in coverage and homogeneity, but no clinically impactful reduction in OAR doses.

A fantastic prospective report on H&N #reirradiation from the Tata Memorial group, one of the largest prospective H&N ReRT reports published. 📌 Patient selection = Crucial. Looking forward to detailed reporting of cumulative RT1 and RT2 dosimetry! https://t.co/K1ezodld7o